BioCryst Pharmaceuticals, Inc.
As of Oct 22, 2026, BioCryst Pharmaceuticals is in Stage 3, the topping phase, now in week 6 (since Sep 17, 2026). It closed at $7.78, 30.0% below its 52-week high and below its 200-day average, which is rising.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BCRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BCRX among Drug Manufacturers - Specialty & Generic23rd of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …23 | BCRX | Stage 3 · wk 6 | 63 | −9.2% |
BioCryst Pharmaceuticals: quick answers
What stage is BioCryst Pharmaceuticals in?
As of Oct 22, 2026, BioCryst Pharmaceuticals (BCRX) is in Stage 3, the topping phase. It entered Stage 3 on Sep 17, 2026 and is in week 6. What the four stages mean
Is BioCryst Pharmaceuticals in an uptrend?
Its uptrend has stalled. BioCryst Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 10.8% below its 200-day average, which is rising.
How far is BioCryst Pharmaceuticals from its 52-week high?
BioCryst Pharmaceuticals closed at $7.78 on Oct 22, 2026, 30.0% below its 52-week high of $11.11. Its 52-week low is $6.24.
How has BioCryst Pharmaceuticals performed over the past year?
As of Oct 22, 2026, BioCryst Pharmaceuticals is up 11.3% over the past year and up 3.7% so far in 2026.
Which sector and industry is BioCryst Pharmaceuticals in?
BioCryst Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.